ERBB2 and lung carcinoma: Interestingly, at the last European Lung Cancer Conference (ELCC 2025), Girard et al. reported an update to this trial, showing that BAY2927088 attained an ORR of 70.5% and mDOR of 8.7 months in the cohort D (44 patients with HER2 MUT NSCLC naïve to anti-HER2 ADCs) and an ORR of 35.3% with a mDOR of 9.5 months in the cohort E (34 patients with HER2 MUT NSCLC previously treated with anti-HER2 ADCs) [83].